Crystalizing the foundations of better antihistamines

November 21, 2011
Figure 1: The crystal structure of H1R with bound doxepin, showing the position of tryptophan and phosphate. Credit: 2011 So Iwata

Researchers in Japan have solved the structure of a complex between the antihistamine drug doxepin and its target receptor histamine H1 receptor (H1R)1. Led by So Iwata of Kyoto University and the RIKEN Systems and Structural Biology Center in Yokohama, the team’s findings should aid the development of better treatments for allergies and inflammation.

Histamine, which is released by mast cells of the immune system, is an important mediator of allergic and inflammatory reactions. It exerts its effects by activating cell-surface receptors, thereby triggering cell signaling events. Of the four known human histamine receptor types, H1R is expressed by various tissues, including airways, the vasculature, and the brain.

Pharmacologists have developed various antihistamine drugs that interfere with histamine–receptor interactions. “Many of us will have taken antihistamines to alleviate the symptoms of hay fever, for example, or to stop the swelling and itchiness caused by insect bites,” Iwata says.

Iwata and his collaborators solved the structure of H1R with bound doxepin using x-ray crystallography. Like all proteins, H1R is composed of amino-acid building blocks. The amino acid tryptophan is found at a particular position in H1R and is known to be important for receptor activation. The researchers revealed that doxepin sits deep within a binding pocket in the receptor, where it interacts directly with this key amino acid (Fig. 1), helping to explain its pharmacological activity.

Doxepin was one of the first antihistamines that effectively blocks histamine receptor activation. Unfortunately, however, these drugs also bind other related receptors. “This low selectivity along with their ability to enter the brain means that these first-generation drugs have considerable side effects such as sedation, mouth dryness, and heart arrhythmias,” explains Iwata.

The researchers’ structural findings suggested that the low selectivity of doxepin is due to the hydrophobic (‘water hating’) nature of the binding pocket, a characteristic found in other receptors to which the drug binds. However, they found that the binding pocket of H1R has a distinctive region occupied by the negatively charged ion phosphate. Through molecular modeling, they demonstrated that the second-generation drugs such as olopatadine would interact with this region, which is not conserved in other related receptors. This explains why these drugs are more selective and have fewer side effects compared with doxepin.

“Our findings demonstrate how minor differences in affect drug selectivity and will be useful in the development of the next generation of antihistamines,” says Iwata.

Explore further: Determining the structure of nuclear receptor has implications for a host of diseases

More information: Shimamura, T., et al. Structure of the human histamine H1 receptor complex with doxepin. Nature 475, 65–70 (2011).

Related Stories

Recognizing pathogenic invaders

October 21, 2011

Researchers in Japan have determined the structural basis of the molecular defense system that protects insects from pathogens1, which provides clarity on the molecular binding that underpins this defense system.

Recommended for you

Brazilian wasp venom kills cancer cells by opening them up

September 1, 2015

The social wasp Polybia paulista protects itself against predators by producing venom known to contain a powerful cancer-fighting ingredient. A Biophysical Journal study published September 1 reveals exactly how the venom's ...

Naturally-occurring protein enables slower-melting ice cream

August 31, 2015

(Phys.org)—Scientists have developed a slower-melting ice cream—consider the advantages the next time a hot summer day turns your child's cone with its dream-like mound of orange, vanilla and lemon swirls with chocolate ...

Antibody-making bacteria promise drug development

August 31, 2015

Monoclonal antibodies, proteins that bind to and destroy foreign invaders in our bodies, routinely are used as therapeutic agents to fight a wide range of maladies including breast cancer, leukemia, asthma, arthritis, psoriasis, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.